Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
ATM Grupa SA
WSE:ATG
|
PL |
Molecular Partners AG
EPS (Diluted)
Molecular Partners AG
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
EPS (Diluted)
-CHf1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
EPS (Diluted)
-$6
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-26%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
EPS (Diluted)
CHf2
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
EPS (Diluted)
CHf0
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
EPS (Diluted)
CHf0
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
EPS (Diluted)
-CHf1
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's EPS (Diluted)?
EPS (Diluted)
-1.7
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's EPS (Diluted) amounts to -1.7 CHF.
What is Molecular Partners AG's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
8%
Over the last year, the EPS (Diluted) growth was -4%.
